A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs
Svetlana B Panina, Natalia Baran, Fabio H Brasil da Costa, Marina Konopleva, Natalia V Kirienko, Svetlana B Panina, Natalia Baran, Fabio H Brasil da Costa, Marina Konopleva, Natalia V Kirienko
Abstract
Mitochondria play a central and multifunctional role in the progression of tumorigenesis. Although many recent studies have demonstrated correlations between mitochondrial function and genetic makeup or originating tissue, it remains unclear why some cancers are more susceptible to mitocans (anticancer drugs that target mitochondrial function to mediate part or all of their effect). Moreover, fundamental questions of efficacy and mechanism of action in various tumor types stubbornly remain. Here we demonstrate that cancer type is a significant predictor of tumor response to mitocan treatment, and that acute myeloid leukemias (AML) show an increased sensitivity to these drugs. We determined that AML cells display particular defects in mitochondrial metabolism that underlie their sensitivity to mitocan treatment. Furthermore, we demonstrated that combinatorial treatment with a mitocan (CCCP) and a glycolytic inhibitor (2-deoxyglucose) has substantial synergy in AML cells, including primary cells from patients with AML. Our results show that mitocans, either alone or in combination with a glycolytic inhibitor, display anti-leukemia effects in doses much lower than needed to induce toxicity against normal blood cells, indicating that mitochondria may be an effective and selective therapeutic target.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
References
- Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–4646. doi: 10.1038/sj.onc.1209597.
- Sánchez-Mendoza SE, Rego EM. Targeting the mitochondria in acute myeloid leukemia. Appl. Cancer Res. 2017;37:22. doi: 10.1186/s41241-017-0022-z.
- Lee HC, Wei YH. Mitochondrial DNA instability and metabolic shift in human cancers. Int J. Mol. Sci. 2009;10:674–701. doi: 10.3390/ijms10020674.
- Zorova LD, et al. Mitochondrial membrane potential. Anal. Biochem. 2018;552:50–59. doi: 10.1016/j.ab.2017.07.009.
- Cui Q, Wen S, Huang P. Targeting cancer cell mitochondria as a therapeutic approach: recent updates. Future Med. Chem. 2017;9:929–949. doi: 10.4155/fmc-2017-0011.
- Neuzil J, Dong LF, Rohlena J, Truksa J, Ralph SJ. Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion. 2013;13:199–208. doi: 10.1016/j.mito.2012.07.112.
- Basak NP, Banerjee S. Mitochondrial dependency in progression of acute myeloid leukemia. Mitochondrion. 2015;21:41–48. doi: 10.1016/j.mito.2015.01.006.
- Hahn T, et al. Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors. Curr. Pharm. Biotechnol. 2013;14:357–376. doi: 10.2174/1389201011314030010.
- Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166:555–566. doi: 10.1016/j.cell.2016.07.002.
- Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer. 2006;6:813–823. doi: 10.1038/nrc1951.
- Shankavaram UT, et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genom. 2009;10:277. doi: 10.1186/1471-2164-10-277.
- Wang L, et al. Oxidative degradation of polyamines by serum supplement causes cytotoxicity on cultured cells. Sci. Rep. 2018;8:10384. doi: 10.1038/s41598-018-28648-8.
- Mahbub AA, Le Maitre CL, Haywood-Small SL, Cross NA, Jordan-Mahy N. Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines. Cell Death Discov. 2015;1:15043. doi: 10.1038/cddiscovery.2015.43.
- Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose-response analysis using R. PLoS ONE10, e0146021 (2015).
- Wheeler MW, Park RM, Bailer AJ. Comparing median lethal concentration values using confidence interval overlap or ratio tests. Environ. Toxicol. Chem. 2006;25:1441–1444. doi: 10.1897/05-320R.1.
- Ritz C, Streibig JC. From additivity to synergism—a modelling perspective. Synergy. 2014;1:22–29. doi: 10.1016/j.synres.2014.07.010.
- Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413–2415. doi: 10.1093/bioinformatics/btx162.
- Mei H, et al. Reduced mtDNA copy number increases the sensitivity of tumor cells to chemotherapeutic drugs. Cell Death Dis. 2015;6:e1710. doi: 10.1038/cddis.2015.78.
- Pardee TS, et al. A Phase I Study of CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. Clin. Cancer Res. 2018;24:2060–2073. doi: 10.1158/1078-0432.CCR-17-2282.
- Pollyea DA, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 2018;24:1859–1866. doi: 10.1038/s41591-018-0233-1.
- Cang S, Iragavarapu C, Savooji J, Song Y, Liu D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J. Hematol. Oncol. 2015;8:129. doi: 10.1186/s13045-015-0224-3.
- Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018;132:1007–1012. doi: 10.1182/blood-2018-03-828269.
- Jia L, Gribben JG. Dangerous power: mitochondria in CLL cells. Blood. 2014;123:2596–2597. doi: 10.1182/blood-2014-03-558965.
- Mailloux RJ, McBride SL, Harper ME. Unearthing the secrets of mitochondrial ROS and glutathione in bioenergetics. Trends Biochem. Sci. 2013;38:592–602. doi: 10.1016/j.tibs.2013.09.001.
- Wu YT, et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J. Biol. Chem. 2010;285:10850–10861. doi: 10.1074/jbc.M109.080796.
- Antczak C, Takagi T, Ramirez CN, Radu C, Djaballah H. Live-cell imaging of caspase activation for high-content screening. J. Biomol. Screen. 2009;14:956–969. doi: 10.1177/1087057109343207.
- Stack JH, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. 2005;175:2630–2634. doi: 10.4049/jimmunol.175.4.2630.
- Lu SZ, Harrison-Findik DD. Autophagy and cancer. World J. Biol. Chem. 2013;4:64–70. doi: 10.4331/wjbc.v4.i3.64.
- Yan C, Li TS. Dual role of mitophagy in cancer drug resistance. Anticancer Res. 2018;38:617–621. doi: 10.21873/anticanres.13034.
- Jitschin R, et al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 2014;123:2663–2672. doi: 10.1182/blood-2013-10-532200.
- Sriskanthadevan S, et al. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood. 2015;125:2120–2130. doi: 10.1182/blood-2014-08-594408.
- Vélez J, et al. Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells. Front Oncol. 2013;3:67. doi: 10.3389/fonc.2013.00067.
- Gorini S, et al. Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. Oxid. Med. Cell Longev. 2018;2018:7582730. doi: 10.1155/2018/7582730.
- Kluza J, et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene. 2004;23:7018–7030. doi: 10.1038/sj.onc.1207936.
- Yan C, et al. Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from HCT8 human colorectal cancer cells. Cancer Lett. 2017;388:34–42. doi: 10.1016/j.canlet.2016.11.018.
- Shin HJ, et al. Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53. Sci. Rep. 2015;5:15798. doi: 10.1038/srep15798.
- Lee S, Zhang C, Liu X. Role of glucose metabolism and ATP in maintaining PINK1 levels during Parkin-mediated mitochondrial damage responses. J. Biol. Chem. 2015;290:904–917. doi: 10.1074/jbc.M114.606798.
- Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011;435:297–312. doi: 10.1042/BJ20110162.
- Roy Chowdhury S, Banerji V. Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia. Oxid. Med. Cell Longev. 2018;2018:2426712. doi: 10.1155/2018/2426712.
- Brookes PS. Mitochondrial H(+) leak and ROS generation: an odd couple. Free Radic. Biol. Med. 2005;38:12–23. doi: 10.1016/j.freeradbiomed.2004.10.016.
- Cheng J, et al. Mitochondrial proton leak plays a critical role in pathogenesis of cardiovascular diseases. Adv. Exp. Med. Biol. 2017;982:359–370. doi: 10.1007/978-3-319-55330-6_20.
- Dar S, et al. Bioenergetic adaptations in chemoresistant ovarian cancer cells. Sci. Rep. 2017;7:8760. doi: 10.1038/s41598-017-09206-0.
- Pfleger J, He M, Abdellatif M. Mitochondrial complex II is a source of the reserve respiratory capacity that is regulated by metabolic sensors and promotes cell survival. Cell Death Dis. 2015;6:e1835. doi: 10.1038/cddis.2015.202.
- Cheng G, et al. Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br. J. Cancer. 2014;111:85–93. doi: 10.1038/bjc.2014.272.
- Cheng G, et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 2012;72:2634–2644. doi: 10.1158/0008-5472.CAN-11-3928.
- Hao JH, Yu M, Liu FT, Newland AC, Jia L. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res. 2004;64:3607–3616. doi: 10.1158/0008-5472.CAN-03-3648.
- Roberts DJ, Miyamoto S. Hexokinase II integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy. Cell Death Differ. 2015;22:248–257. doi: 10.1038/cdd.2014.173.
- Chen Z, Zhang H, Lu W, Huang P. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim. Biophys. Acta. 2009;1787:553–560. doi: 10.1016/j.bbabio.2009.03.003.
Source: PubMed